Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Trinity Biotech PLC (TRIB : NSDQ)
 
 • Company Description   
Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.

Number of Employees: 401

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.75 Daily Weekly Monthly
20 Day Moving Average: 2,404,859 shares
Shares Outstanding: 18.05 (millions)
Market Capitalization: $13.54 (millions)
Beta: 0.80
52 Week High: $3.44
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.92% 11.54%
12 Week 33.93% 12.36%
Year To Date -14.79% -20.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
IDA BUSINESS PARK BRAY
-
WICKLOW,L2 A98 H5C8
IRL
ph: 353-1276-9800
fax: 353-1276-9888
investorrelations@trinitybiotech.com http://www.trinitybiotech.com
 
 • General Corporate Information   
Officers
John Gillard - Chief Executive Officer
Louise Tallon - Interim Chief Financial Officer
Gary Keating - Chief Technology Officer
Tom Lindsay - Independent Director
Andrew Omidvar - Independent Director

Peer Information
Trinity Biotech PLC (BJCT)
Trinity Biotech PLC (CADMQ)
Trinity Biotech PLC (APNO)
Trinity Biotech PLC (UPDC)
Trinity Biotech PLC (IMTIQ)
Trinity Biotech PLC (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 896438504
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 18.05
Most Recent Split Date: 2.00 (0.20:1)
Beta: 0.80
Market Capitalization: $13.54 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 20.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.22
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: -137.21%
Sales Growth
vs. Year Ago Period: 18.09%
vs. Previous Quarter: 4.65%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -27.43
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.28
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 0.68
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -42.94
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -51.64
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -49.92
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -1.95
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - 1.85
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©